Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-α inhibitor monotherapy and in combination with thiopurines: Analysis of the food and drug administration adverse event reporting system

Journal of Gastrointestinal and Liver Diseases

Volumn 23, Issue 3, 2014, Pages 267-271

  McKenna, Michael R ^a   Stobaugh, Derrick J ^a   Deepak, Parakkal ^b  

^a NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Inflammatory bowel diseases complications; Inflammatory bowel diseases drug therapy; Skin neoplasms chemically induced; Tumor necrosis factor alpha antagonists and inhibitors

Indexed keywords

ANTIINFLAMMATORY AGENT; GASTROINTESTINAL AGENT; PURINE; PURINE DERIVATIVE; STEROID; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; COMPLICATION; DRUG COMBINATION; DRUG SURVEILLANCE PROGRAM; FACTUAL DATABASE; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; MALE; MELANOMA; MIDDLE AGED; RISK; RISK ASSESSMENT; RISK FACTOR; SKIN TUMOR; TIME; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTI-INFLAMMATORY AGENTS; DATABASES, FACTUAL; DRUG THERAPY, COMBINATION; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MELANOMA; MIDDLE AGED; ODDS RATIO; PURINES; RISK ASSESSMENT; RISK FACTORS; SKIN NEOPLASMS; STEROIDS; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 84906859283     PISSN: 18418724     EISSN: None     Source Type: Journal    
DOI: 10.1543/jgld.2014.1121     Document Type: Article

References (34)

1. Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of nonmelanoma skin cancer in the United States, 2006. Arch Dermatol 2010;146:283-287
2. Christenson LJ, Borrowman TA, Vachon CM, et al. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA 2005;294):681-690
3. Langholz E, Munkholm P, Davidesen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology 1994;107:3-11
4. Singh H, Nugent Z, Demers AA, Bernstein CN. Increased risk of nonmelanoma skin cancers among individuals with inflammatory bowel disease. Gastroenterology 2011;141:1612-1620
5. Ekbom A., Helmick C., Zack M., Adami HO. Extracolonic malignancies in inflammatory bowel disease. Cancer 1991;67: 2015-2019
6. Peyrin-Biroulet L, Khosrotehrani K, Carrat F, et al. Increased risk for non-melanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease. Gastroenterology 2011;141:1621-1628
7. Bernstein CN, Blanchard JF, Rawsthorne P, Yu N. The prevalence of extraintestinal diseases in inflammatory bowel disease: a populationbased study. Am J Gastroenterology 2001;96:1116-1122
8. Long MD, Martin CF, Pipkin CA, Herfarth HH, Sandler RS, Kappelman MD. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012;143:390-399
9. Winther KV, Jess T, Langholz E, Munkholm P, Binder V. Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol 2004;2:1088-1095
10. Askling J, Fahrbach K, Nordstrom B, Ross S, Schmid CH, Symmons D. Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: metaanalysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data. Pharmacoepidemiol Drug Saf 2011;20:119-130
11. Fidder H, Schnitzler F, Ferrante M, et al. Long-term safety of infliximab for the treatment of inflammatory bowel disease: A single-centre cohort study. Gut 2009;58:501-508
12. Ochsenkuhn T, Steinborn A, Beigel F, et al. Rate of Malignancies and Infections in a Large Single Center Cohort of IBD Patients Treated With Thiopurines and Anti-TNF-αntibodies. Gastroenterology 2011;144:S-773
13. Haynes K, Beukelman T, Curtis JR, et al. Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases. Arthritis Rheum 2013;65:48-58
14. Food and Drug Administration Adverse Event Reporting System (FAERS) data f iles. http://www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/defalut.htm. Accessed June 20, 2013
15. Mason M, Siegel C. Do inflammatory bowel disease therapies cause cancer? Inflamm Bowel Dis 2004;19;1306-1321
16. Deepak P, Sifuentes H, Sherid M, Stobaugh D, Sadozai Y, Ehrenpreis ED. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study. Am J Gastroenterol 2013;108:99-105
17. Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH. Performance of pharmacovigilance signal-detection algorithms for the FDA adverse event reporting system. Clin Pharmacol Ther 2013;93:539-546
18. Stobaugh DJ, Deepak P, Ehrenpreis ED. Alleged isotretinoin-associated inflammatory bowel disease: disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System. J Am Acad Dermatol 2013;69:393-398
19. Hakam A, Yeatman TJ, Lu L, et al. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol 1999;30:1128-1133
20. Turner BC, Haffty BG, Narayanan L, et al. Insulin-like growth factor-I receptor overexpression mediates cellular radio resistance and localbreast cancer recurrence after lumpectomy and radiation. Cancer Res 1997;57:3079-3083
21. Satyamoorthy K, Li G, Vaidya B, Patel D, Herlyn M. Insulin-like growth factor-1 induces survival and growth of biologically early melanoma cells through both the mitogen-activated protein kinase and betacatenin pathways. Cancer Res 2001;61:7318-7324
22. Frost RA, Nystrom GJ, Lang CH. Tumor necrosis factor-alpha decreases insulin-like growth factor-I messenger ribonucleic acid expression in C2C12 myoblasts via a Jun N-terminal kinase pathway. Endocrinology 2003;144:1770-1779
23. Allen DB, Julius JR, Breen TJ, Attie KM. Treatment of glucocorticoidinduced growth suppression with growth hormone. National Cooperative Growth Study. J Clin Endocrinol Metab 1998;83:2824-2829
24. Parrish JA. Immunosuppression, skin cancer, and ultraviolet A radiation. N Engl J Med 2005;353:2712-2713
25. Pasternak B, Svanstrom H, Schmiegelow K, Jess T, Hviid A. Use of azathioprine and the risk of cancer in inflammatory bowel disease. Am J Epidemiol 2013;177:1296-1305
26. Setshedi M, Epstein D, Winter TA, Myer L, Watermeyer G, Hift R. Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study. J Gastroenterol Hepatol 2012;27:385-389
27. Attard NR, Karren P. UVA photosensitization of thiopurines and skin cancer in organ transplant recipients. Photochem Photobiol Sci 2012;11:62-68
28. Gale EA. Collateral damage: the conundrum of drug safety. Diabetologia 2009;52:1975-1982
29. Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006;29:385-396
30. Salk A, Stobaugh DJ, Deepak P, Ehrenpreis ED. Ischaemic colitis in rheumatoid arthritis patients receiving tumour necrosis factor-α inhibitors: an analysis of reports to the US FDA Adverse Event Reporting System. Drug Saf 2013;36:329-334
31. Long M, Nelson K, Ponder A, Kollitz K, Kappelman M. Characteristics of malignant melanoma in patients with Inflammatory Bowel Diseases. Inflamm Bowel Dis 2011;17:S28-S29
32. Bickston SJ. Infliximab for ulcerative colitis induction of remission and maintenance therapy. Gastroenterol Hepatol 2007;3:55-56
33. Ulrich C, Degen A, Patel MJ, Stockfleth E. Sunscreens in organ transplant patients. Nephrol Dial Transplant 2008;23:1805-1808
34. Otley CC. Organization of a specialty clinic to optimize the care of organ transplant recipients at risk for skin cancer. Dermatol Surg 2000;26:709-712.